Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00907192
Other study ID # 2009-0019
Secondary ID
Status Completed
Phase N/A
First received May 20, 2009
Last updated June 14, 2013
Start date May 2009
Est. completion date June 2012

Study information

Verified date June 2013
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

Primary Objective:

1. To determine the frequency of self-reported over and under use of opioid analgesics in patients with advanced cancer. Patients with advanced cancer are those patients who have been described to have either one of the following: recurrent disease, those that have failed multiple chemotherapies (more than second line therapy), locally advanced disease, and metastatic disease.

Secondary Objectives:

1. To determine the association between patients' knowledge, attitudes and beliefs about opioids, and frequency of deviation in opioid use with patients' demographic information.

2. To determine association between alcohol abuse/chemical coping and self-reported deviations in opioid use.

3. To determine the association between the use of opioids and patient-related barriers to opioid use.


Description:

Screening:

Before you start the study, the research nurse will check your medical record to see if you are eligible to take part in this study. Information will be recorded about your demographics (such as age, marital status, ethnicity, education level, and gender), medical history (such as the type of cancer and level of pain), and prescriptions (such as the name of any opioid drugs, doses, and schedule).

Interview Process:

If you are found to be eligible to take part in this study, you will be interviewed by the study staff before a regular visit with your doctor. You will be asked some questions about your use of pain drugs and other knowledge and/or attitudes that you may have about them. You may also be asked for general information (such as your age, marital status, or educational level) if it was not available in your chart and medical record.

Questionnaires:

After the interview, you will complete 5 short questionnaires about your use of pain drugs, your attitudes about the pain drugs and their use, and concerns that you may have about your use of these pain drugs.

It will take about 5-10 minutes for the interview and another 10-15 minutes to complete all the questionnaires.

Your interview and questionnaire responses will not be shared with your regular doctor unless the study staff feels that you maybe be at harm. If you feel you need a doctor's opinion about anything that is asked in the interview and/or questionnaires, please contact your doctor.

Confidentiality:

Your interview and questionnaire responses will only be used for this research study and will not be shared with your family members.

Length of Study:

After completing the interview and questionnaires, your participation in this study will be over.

This is an investigational study. Up to 200 patients will take part in this study. All will be enrolled at M. D. Anderson.


Recruitment information / eligibility

Status Completed
Enrollment 201
Est. completion date June 2012
Est. primary completion date June 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patients must be at least 18 years old and have a diagnosis of advanced cancer.

2. Patients must be given prescriptions for around the clock (ATC) and as needed (for breakthrough pain) oral opioids for cancer pain on the previous visit to the Palliative Care Clinic.

3. Patients must be able to understand, read, write, and speak English.

4. Patients must have no clinical evidence of cognitive impairment, as determined by the primary palliative care physician.

5. Patients must sign an informed consent.

Exclusion Criteria:

1. Patients who have the caregiver as the primary person that does the management of opioid medication intake will be excluded as analysis is focused on patients' and not the family or caregivers' knowledge, attitudes and beliefs as it relates to the primary objective.

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Behavioral:
Personal Interview
Interview questions about use of pain drugs and other knowledge and/or attitudes about them. Take about 5-10 minutes to complete.
Questionnaire
5 short questionnaires about use of pain drugs, attitudes about the pain drugs and their use, and concerns about use of these pain drugs. Take about 10-15 minutes to complete.

Locations

Country Name City State
United States UT MD Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Persons with Advanced Cancer who Self-report Opioid Analgesics Over/Under 2 Years No
See also
  Status Clinical Trial Phase
Completed NCT01213238 - Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab Phase 1
Recruiting NCT02160366 - Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients
Completed NCT00379353 - The Effects of Thalidomide on Symptom Clusters Phase 2
Completed NCT00903708 - LY2275796 in Advanced Cancer Phase 1
Terminated NCT00499382 - Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging N/A
Completed NCT02459964 - Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain Phase 4
Completed NCT01430572 - Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients Phase 1
Completed NCT02561234 - A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT01375114 - The Effects of Ginseng on Cancer-Related Fatigue Phase 2
Completed NCT01454804 - Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors Phase 1
Completed NCT01201694 - Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L) Phase 1
Completed NCT02801045 - Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient N/A
Completed NCT02873975 - A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency Phase 2
Completed NCT01983969 - Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Phase 1/Phase 2
Completed NCT02272595 - Rational Therapeutics Based on Matched Tumor and Normal Tissue
Active, not recruiting NCT01999491 - A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma Phase 1
Recruiting NCT03375983 - Plasmodium Immunotherapy for Advanced Cancers Phase 1/Phase 2
Completed NCT02571036 - A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Phase 1
Withdrawn NCT01608139 - Study of Curcumin, Vorinostat, and Sorafenib Phase 1
Completed NCT01024166 - Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study N/A